Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07073820 · ClinicalTrials.gov registry record · Phase 2
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
A Phase 2 study of Pulmonary Hypertension, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 20
- Study locations
NCT07073820: Recruiting Phase 2 study of Pulmonary Hypertension, sponsored by Pfizer.
NCT07073820 is a Phase 2 study of Pulmonary Hypertension that is actively recruiting participants, run by Pfizer. The registered enrollment target is 36 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07073820, a Phase 2 study of Pulmonary Hypertension, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure makes it harder for the heart to pump blood through those lungs, potentially damaging the right side of the heart. This is an open-label study. Which means that both the healthcare providers and the study participants are aware of the medicine being given. This study is also an extension study with study medicine (PF-07868489). An extension study allows patients from an earlier clinical study (also called as qualifying study) to continue participating to assess long-term benefits and safety of the medicine.
Conditions Studied
Interventions
- DRUG PF-07868489
Study Locations (20)
California
- UCSF Health St. Mary's Hospital - San Francisco
- Heart and Vascular Center - San Francisco
Kentucky
- Norton Hospital - Louisville
- Norton Pulmonary Specialists - Louisville
Rhode Island
- Rhode Island Hospital - Providence
- Center for Advanced Lung Care - Providence
Other
- HUB Hôpital Erasme - Brussels
- UZ Leuven - Leuven
Ontario
- London Health Sciences Centre - University Hospital - London
- London Health Sciences Centre - London
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
New South Wales
- Royal Prince Alfred Hospital - Camperdown
Guangdong
- Guangdong Provincial People's Hospital - Guangzhou
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-11-10 |
| Est. Completion | 2028-07-18 |
| Phase | Phase 2 |
What NCT07073820 shows while recruiting
NCT07073820 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which PF-07868489 is the first listed.
NCT07073820 names 20 study sites across 15 states, led by California, Kentucky, Rhode Island.
Frequently Asked Questions
What is clinical trial NCT07073820 about?
NCT07073820 is a clinical study titled "A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489". The purpose of this study is to learn about the long-term safety, tolerability and effects of the study medicine (PF-07868489) for the possible treatment of PAH. PAH is a condition in which there is high blood pressure in the arteries that carry blood from the heart to the lungs. This high pressure ...
What is the current status of trial NCT07073820?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2025-11-10. Estimated completion is 2028-07-18.
What conditions does trial NCT07073820 study?
This clinical trial studies the following conditions: Pulmonary Hypertension.
What interventions are being tested in trial NCT07073820?
The interventions under investigation include: PF-07868489 (DRUG).
Who is sponsoring clinical trial NCT07073820?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07073820 being conducted?
This trial has 20 study locations across California, Colorado, Kentucky, Rhode Island, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07073820's enrollment target sits among peer trials
36 44th of 72 higher than 28 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
-
Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis
RECRUITING · Phase 2
-
Xenon MRI Pulm Hypertension
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
RECRUITING · Phase 2
-
Metformin for Pulmonary Hypertension HFpEF
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI